Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $168
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Stephanie Davis maintains an Equal-Weight rating on Quest Diagnostics and raises the price target from $154 to $168.
October 23, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has maintained its Equal-Weight rating on Quest Diagnostics but increased the price target from $154 to $168, indicating a positive outlook.
The increase in price target from $154 to $168 by Barclays suggests a positive outlook for Quest Diagnostics, which could lead to a short-term increase in stock price. The maintained Equal-Weight rating indicates a balanced view, but the raised target shows confidence in potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100